Table of Content

1. Key Insights

2. Executive Summary of Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity

3. Competitive Intelligence Analysis for Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity

4. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity: Market Overview at a Glance
4.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Share (%) Distribution in 2017
4.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Share (%) Distribution in 2030

5. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Treatment and Management
8.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Treatment

11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report

12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report

13. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity: Seven Major Market Analysis
13.1. Key Findings
13.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size in 7MM
13.3. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in the United States
15.1.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in Germany
15.3.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in France
15.4.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in Italy
15.5.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in Spain
15.6.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in the United Kingdom
15.7.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Total Market Size in Japan
15.8.3. Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight



List of Figures


Figure 1 : 7MM Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology (2017-2030)
Figure 2 : 7MM Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases (2017-2030)
Figure 3 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in the United States (2017-2030)
Figure 4 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Germany (2017-2030)
Figure 6 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in France (2017-2030)
Figure 8 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Italy (2017-2030)
Figure 10 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Spain (2017-2030)
Figure 12 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in the UK (2017-2030)
Figure 14 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in the UK (2017-2030)
Figure 15 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Japan (2017-2030)
Figure 16 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 17 : Drug Name, Clinical Trials by Recruitment status
Figure 18 : Drug Name, Clinical Trials by Zone
Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Figure 22 : United States Market Size in USD, Million (2017-2030)
Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Figure 24 : Germany Market Size in USD, Million (2017-2030)
Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Figure 26 : France Market Size in USD, Million (2017-2030)
Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
Figure 28 : Italy Market Size in USD, Million (2017-2030)
Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Figure 30 : Spain Market Size in USD, Million (2017-2030)
Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Figure 34 : Japan Market Size in USD, Million (2017-2030)
Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)


List of Tables


Table 1 : 7MM Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology (2017-2030)
Table 2 : 7MM Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases (2017-2030)
Table 3 : Disease% Epidemiology in the United States (2017-2030)
Table 4 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Germany (2017-2030)
Table 6 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in France (2017-2030)
Table 8 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in France (2017-2030)
Table 9 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Italy (2017-2030)
Table 10 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Spain (2017-2030)
Table 12 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in the UK (2017-2030)
Table 14 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in the UK (2017-2030)
Table 15 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Epidemiology in Japan (2017-2030)
Table 16 : Pro-Opiomelanocortin (POMC) Deficiency Obesity & Leptin Receptor (LEPR) Deficiency Obesity Diagnosed and Treatable Cases in Japan (2017-2030)
Table 17 : Drug Name, Clinical Trials by Recruitment status
Table 18 : Drug Name, Clinical Trials by Zone
Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Table 20 : Region-wise Market Size in USD, Million (2017-2030)
Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Table 22 : United States Market Size in USD, Million (2017-2030)
Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Table 24 : Germany Market Size in USD, Million (2017-2030)
Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Table 26 : France Market Size in USD, Million (2017-2030)
Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
Table 28 : Italy Market Size in USD, Million (2017-2030)
Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Table 30 : Spain Market Size in USD, Million (2017-2030)
Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Table 34 : Japan Market Size in USD, Million (2017-2030)
Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)